Clinical value of detecting autoantibodies against β1-, β2-, and α1-adrenergic receptors in carvedilol treatment of patients with heart failure

Dong-Yan HOU; Lin XU; Zhi-Yong ZHANG; Xiao-Rong XU; Xin WANG; Juan ZHANG; Jia-Mei LIU; Hua WANG; Jin CHEN; Lin ZHANG

doi:10.11909/j.issn.1671-5411.2020.06.002

🤖This page has been translated by AI and may contain inaccuracies. Please refer to the original content for clarification.

Home>Articles>Clinical value of detecting autoantibodies against β1-, β2-, and α1-adrenergic receptors in carvedilol treatment of patients with heart failure

DOI: 10.11909/j.issn.1671-5411.2020.06.002

Clinical value of detecting autoantibodies against β1-, β2-, and α1-adrenergic receptors in carvedilol treatment of patients with heart failure

Dong-Yan HOU

Lin XU

Zhi-Yong ZHANG

Xiao-Rong XU

Xin WANG

Juan ZHANG

Jia-Mei LIU

Hua WANG

Jin CHEN

Lin ZHANG

Keywords：Adrenergic receptorsAutoantibodiesCardiac functionCarvedilolHeart failure

Publication Date：2020-06-28

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：8( 305-312 )

Journal of Geriatric Cardiology

SCICSCD

ISSN：1671-5411

Year, Vol.(Issue)：2020,17(6)